Brought to you by 
BioMarin buys Glyko for $14.5mm
08 Apr 2002
Executive Summary
BioMarin Pharmaceutical Inc. (carbohydrate enzyme therapeutics) has agreed to acquire Glyko Inc., BioMarin's lead investor, for $14.5mm worth of BioMarin stock and the assumption of certain employee stock options.
Deal Industry
- In Vitro Diagnostics
- Research, Analytical Equipment & Supplies
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
BioMarin buys Glyko for $14.5mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice